Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Obeticholic acid（OCA）
1.2.3 Selonsertib
1.3 Market by Application
1.3.1 Global Nonalcoholic Steatohepatitis (NASH) Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Perspective (2018-2033)
2.2 Nonalcoholic Steatohepatitis (NASH) Growth Trends by Region
2.2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Region (2018-2023)
2.2.3 Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Region (2024-2033)
2.3 Nonalcoholic Steatohepatitis (NASH) Market Dynamics
2.3.1 Nonalcoholic Steatohepatitis (NASH) Industry Trends
2.3.2 Nonalcoholic Steatohepatitis (NASH) Market Drivers
2.3.3 Nonalcoholic Steatohepatitis (NASH) Market Challenges
2.3.4 Nonalcoholic Steatohepatitis (NASH) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue
3.1.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue (2018-2023)
3.1.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Players (2018-2023)
3.2 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nonalcoholic Steatohepatitis (NASH) Revenue
3.4 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio
3.4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nonalcoholic Steatohepatitis (NASH) Revenue in 2022
3.5 Nonalcoholic Steatohepatitis (NASH) Key Players Head office and Area Served
3.6 Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
3.7 Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Type
4.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Type (2018-2023)
4.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2024-2033)
5 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Application
5.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Application (2018-2023)
5.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size (2018-2033)
6.2 North America Nonalcoholic Steatohepatitis (NASH) Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2018-2023)
6.4 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size (2018-2033)
7.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2018-2023)
7.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size (2018-2033)
8.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2018-2023)
8.4 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size (2018-2033)
9.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2018-2023)
9.4 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size (2018-2033)
10.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2018-2023)
10.4 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Introduction
11.1.4 AstraZeneca Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.1.5 AstraZeneca Recent Development
11.2 Arena Pharmaceuticals
11.2.1 Arena Pharmaceuticals Company Detail
11.2.2 Arena Pharmaceuticals Business Overview
11.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.2.4 Arena Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.2.5 Arena Pharmaceuticals Recent Development
11.3 GSK
11.3.1 GSK Company Detail
11.3.2 GSK Business Overview
11.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Introduction
11.3.4 GSK Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.3.5 GSK Recent Development
11.4 Novo Nordisk
11.4.1 Novo Nordisk Company Detail
11.4.2 Novo Nordisk Business Overview
11.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Introduction
11.4.4 Novo Nordisk Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.4.5 Novo Nordisk Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Introduction
11.5.4 Roche Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.5.5 Roche Recent Development
11.6 Vivus
11.6.1 Vivus Company Detail
11.6.2 Vivus Business Overview
11.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Introduction
11.6.4 Vivus Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.6.5 Vivus Recent Development
11.7 Arisaph Pharmaceuticals
11.7.1 Arisaph Pharmaceuticals Company Detail
11.7.2 Arisaph Pharmaceuticals Business Overview
11.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.7.4 Arisaph Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.7.5 Arisaph Pharmaceuticals Recent Development
11.8 Cempra Pharmaceuticals
11.8.1 Cempra Pharmaceuticals Company Detail
11.8.2 Cempra Pharmaceuticals Business Overview
11.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.8.4 Cempra Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.8.5 Cempra Pharmaceuticals Recent Development
11.9 Galectin Therapeutics
11.9.1 Galectin Therapeutics Company Detail
11.9.2 Galectin Therapeutics Business Overview
11.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Introduction
11.9.4 Galectin Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.9.5 Galectin Therapeutics Recent Development
11.10 Galmed Pharmaceuticals
11.10.1 Galmed Pharmaceuticals Company Detail
11.10.2 Galmed Pharmaceuticals Business Overview
11.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.10.4 Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.10.5 Galmed Pharmaceuticals Recent Development
11.11 Genfit
11.11.1 Genfit Company Detail
11.11.2 Genfit Business Overview
11.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Introduction
11.11.4 Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.11.5 Genfit Recent Development
11.12 Gilead
11.12.1 Gilead Company Detail
11.12.2 Gilead Business Overview
11.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Introduction
11.12.4 Gilead Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.12.5 Gilead Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Obeticholic acid（OCA）
Table 3. Key Players of Selonsertib
Table 4. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 5. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Region (2018-2023)
Table 8. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Region (2024-2033)
Table 10. Nonalcoholic Steatohepatitis (NASH) Market Trends
Table 11. Nonalcoholic Steatohepatitis (NASH) Market Drivers
Table 12. Nonalcoholic Steatohepatitis (NASH) Market Challenges
Table 13. Nonalcoholic Steatohepatitis (NASH) Market Restraints
Table 14. Global Nonalcoholic Steatohepatitis (NASH) Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Players (2018-2023)
Table 16. Global Top Nonalcoholic Steatohepatitis (NASH) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2022)
Table 17. Ranking of Global Top Nonalcoholic Steatohepatitis (NASH) Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
Table 21. Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2018-2023)
Table 25. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2024-2033)
Table 27. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Application (2018-2023)
Table 29. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Application (2024-2033)
Table 31. North America Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 32. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 38. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 41. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2024-2033) & (US$ Million)
Table 46. AstraZeneca Company Detail
Table 47. AstraZeneca Business Overview
Table 48. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product
Table 49. AstraZeneca Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 50. AstraZeneca Recent Development
Table 51. Arena Pharmaceuticals Company Detail
Table 52. Arena Pharmaceuticals Business Overview
Table 53. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
Table 54. Arena Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 55. Arena Pharmaceuticals Recent Development
Table 56. GSK Company Detail
Table 57. GSK Business Overview
Table 58. GSK Nonalcoholic Steatohepatitis (NASH) Product
Table 59. GSK Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 60. GSK Recent Development
Table 61. Novo Nordisk Company Detail
Table 62. Novo Nordisk Business Overview
Table 63. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product
Table 64. Novo Nordisk Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 65. Novo Nordisk Recent Development
Table 66. Roche Company Detail
Table 67. Roche Business Overview
Table 68. Roche Nonalcoholic Steatohepatitis (NASH) Product
Table 69. Roche Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 70. Roche Recent Development
Table 71. Vivus Company Detail
Table 72. Vivus Business Overview
Table 73. Vivus Nonalcoholic Steatohepatitis (NASH) Product
Table 74. Vivus Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 75. Vivus Recent Development
Table 76. Arisaph Pharmaceuticals Company Detail
Table 77. Arisaph Pharmaceuticals Business Overview
Table 78. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
Table 79. Arisaph Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 80. Arisaph Pharmaceuticals Recent Development
Table 81. Cempra Pharmaceuticals Company Detail
Table 82. Cempra Pharmaceuticals Business Overview
Table 83. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
Table 84. Cempra Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 85. Cempra Pharmaceuticals Recent Development
Table 86. Galectin Therapeutics Company Detail
Table 87. Galectin Therapeutics Business Overview
Table 88. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product
Table 89. Galectin Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 90. Galectin Therapeutics Recent Development
Table 91. Galmed Pharmaceuticals Company Detail
Table 92. Galmed Pharmaceuticals Business Overview
Table 93. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
Table 94. Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 95. Galmed Pharmaceuticals Recent Development
Table 96. Genfit Company Detail
Table 97. Genfit Business Overview
Table 98. Genfit Nonalcoholic Steatohepatitis (NASH) Product
Table 99. Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 100. Genfit Recent Development
Table 101. Gilead Company Detail
Table 102. Gilead Business Overview
Table 103. Gilead Nonalcoholic Steatohepatitis (NASH) Product
Table 104. Gilead Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 105. Gilead Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Nonalcoholic Steatohepatitis (NASH) Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Type: 2022 VS 2033
Figure 3. Obeticholic acid（OCA） Features
Figure 4. Selonsertib Features
Figure 5. Global Nonalcoholic Steatohepatitis (NASH) Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application: 2022 VS 2033
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Online Provider Case Studies
Figure 9. Retail Pharmacy Case Studies
Figure 10. Nonalcoholic Steatohepatitis (NASH) Report Years Considered
Figure 11. Global Nonalcoholic Steatohepatitis (NASH) Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global Nonalcoholic Steatohepatitis (NASH) Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 13. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Region: 2022 VS 2033
Figure 14. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Players in 2022
Figure 15. Global Top Nonalcoholic Steatohepatitis (NASH) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue in 2022
Figure 17. North America Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2018-2033)
Figure 19. United States Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. Canada Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Europe Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2018-2033)
Figure 23. Germany Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. France Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. U.K. Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Italy Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Russia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Nordic Countries Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Share by Region (2018-2033)
Figure 31. China Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Japan Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. South Korea Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. India Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Australia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2018-2033)
Figure 39. Mexico Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Brazil Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2018-2033)
Figure 43. Turkey Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. AstraZeneca Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 46. Arena Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 47. GSK Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 48. Novo Nordisk Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 49. Roche Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 50. Vivus Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 51. Arisaph Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 52. Cempra Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 53. Galectin Therapeutics Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 54. Galmed Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 55. Genfit Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 56. Gilead Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed